Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1998 1
1999 3
2001 1
2002 2
2003 3
2004 2
2005 2
2006 1
2007 2
2008 4
2009 5
2010 2
2011 3
2012 8
2013 4
2014 7
2015 8
2016 8
2017 8
2018 10
2019 10
2020 8
2021 10
2022 15
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for pca and ligand and mutation
Search for PPIA and ligand and mutation instead (2 results)
Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA, Yen AE, Weigel NL. Shafi AA, et al. Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Pharmacol Ther. 2013. PMID: 23859952 Review.
In the United States, prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in males and the second leading cause of cancer-related death for men. ...The primary treatment for metastatic PCa is androgen deprivation therapy (ADT). For the most par …
In the United States, prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in males and the second leading cause …
Endocrine Disruptors and Prostate Cancer.
Corti M, Lorenzetti S, Ubaldi A, Zilli R, Marcoccia D. Corti M, et al. Int J Mol Sci. 2022 Jan 21;23(3):1216. doi: 10.3390/ijms23031216. Int J Mol Sci. 2022. PMID: 35163140 Free PMC article. Review.
In physiological condition, in the prostate epithelium the more-active androgen, the 5alpha-dihydrotestosterone (DHT), formed from testosterone (T) by the 5alpha-reductase enzyme (SRD5A), binds to AR and, upon homodimerization and nuclear translocation, recognizes the promoter of …
In physiological condition, in the prostate epithelium the more-active androgen, the 5alpha-dihydrotestosterone (DHT), formed from testoster …
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
Denmeade SR, Sena LA, Wang H, Antonarakis ES, Markowski MC. Denmeade SR, et al. Oncologist. 2023 Jun 2;28(6):465-473. doi: 10.1093/oncolo/oyad055. Oncologist. 2023. PMID: 37027449 Free PMC article. Review.
All patients eventually develop resistance to primary castrating therapy [ie, castration-resistant PCa (CRPC)]. At this point, they are treated with subsequent lines of secondary AR inhibitory therapies. ...However, the majority of PCas remain addicted to signaling through …
All patients eventually develop resistance to primary castrating therapy [ie, castration-resistant PCa (CRPC)]. At this point, they a …
Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression.
Li S, Wu Z, Ma P, Xu Y, Chen Y, Wang H, He P, Kang Z, Yin L, Zhao Y, Zhang X, Xu X, Ma X, Guan M. Li S, et al. Cell Death Dis. 2017 Oct 12;8(10):e3122. doi: 10.1038/cddis.2017.507. Cell Death Dis. 2017. PMID: 29022918 Free PMC article.
In addition, ectopic expression of WT EphA7 both can delay PCa cell proliferation and could inhibit PCa cell migration and invasion. ...However, expression of these EphA7 mutants in PCa cells has no effect in vivo and in vitro. The expression of EphA7 and eph …
In addition, ectopic expression of WT EphA7 both can delay PCa cell proliferation and could inhibit PCa cell migration and inv …
Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.
Yeh Y, Guo Q, Connelly Z, Cheng S, Yang S, Prieto-Dominguez N, Yu X. Yeh Y, et al. Adv Exp Med Biol. 2019;1210:351-378. doi: 10.1007/978-3-030-32656-2_16. Adv Exp Med Biol. 2019. PMID: 31900917 Review.
Initially, PCa responds to the treatment and regresses. However, PCa almost always develops resistance to androgen deprivation and progresses to castrate-resistant prostate cancer (CRPCa), a currently incurable form of PCa. Wnt/beta-Catenin signaling is frequ …
Initially, PCa responds to the treatment and regresses. However, PCa almost always develops resistance to androgen deprivation …
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.
Isaacsson Velho P, Antonarakis ES. Isaacsson Velho P, et al. Expert Rev Clin Pharmacol. 2018 May;11(5):475-486. doi: 10.1080/17512433.2018.1464388. Epub 2018 Apr 24. Expert Rev Clin Pharmacol. 2018. PMID: 29641940 Free PMC article. Review.
Pharmacological inhibition of immune checkpoint receptors or their ligands represents a transformative breakthrough in the management of multiple cancers. However, immune checkpoint inhibitors have yet to be FDA-approved for the management of metastatic prostate cancer ( …
Pharmacological inhibition of immune checkpoint receptors or their ligands represents a transformative breakthrough in the management …
Constitutive activity of the androgen receptor.
Chan SC, Dehm SM. Chan SC, et al. Adv Pharmacol. 2014;70:327-66. doi: 10.1016/B978-0-12-417197-8.00011-0. Adv Pharmacol. 2014. PMID: 24931201 Free PMC article. Review.
Prostate cancer (PCa) is the most frequently diagnosed cancer in the United States. The androgen receptor (AR) signaling axis is central to all stages of PCa pathophysiology and serves as the main target for endocrine-based therapy. ...
Prostate cancer (PCa) is the most frequently diagnosed cancer in the United States. The androgen receptor (AR) signaling axis is cent …
Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C, Chen J, Chen L. Luo C, et al. Int Immunopharmacol. 2020 Sep;86:106709. doi: 10.1016/j.intimp.2020.106709. Epub 2020 Jun 24. Int Immunopharmacol. 2020. PMID: 32593155
METHODS: Mutation data, gene expression, clinicopathological information were downloaded from The Cancer Genome Atlas (TCGA). ...CONCLUSIONS: The current study comprehensively described the summary of mutation and TMB related DEGs in PCa. TMB was associated w …
METHODS: Mutation data, gene expression, clinicopathological information were downloaded from The Cancer Genome Atlas (TCGA). ...CONC …
Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.
Cuccurullo V, Di Stasio GD, Mansi L. Cuccurullo V, et al. World J Nucl Med. 2018 Apr-Jun;17(2):70-78. doi: 10.4103/wjnm.WJNM_54_17. World J Nucl Med. 2018. PMID: 29719480 Free PMC article. Review.
Natural history of prostate cancer (PCa) is extremely variable, as it ranges from indolent and slow growing tumors to highly aggressive histotypes. Genetic background and environmental factors co-operate to the genesis and clinical manifestation of the tumor and include am …
Natural history of prostate cancer (PCa) is extremely variable, as it ranges from indolent and slow growing tumors to highly aggressi …
Structural Investigations and Binding Mechanisms of Oseltamivir Drug Resistance Conferred by the E119V Mutation in Influenza H7N9 Virus.
Ugbaja SC, Mtambo SE, Mushebenge AG, Appiah-Kubi P, Abubakar BH, Ntuli ML, Kumalo HM. Ugbaja SC, et al. Molecules. 2022 Jul 8;27(14):4376. doi: 10.3390/molecules27144376. Molecules. 2022. PMID: 35889251 Free PMC article.
The decrease in binding affinity (-3.74 kcal/mol) was consistent with RMSD, RMSF, SASA, PCA, and hydrogen bonding profiles, confirming that the E119V mutation conferred lower conformational stability and weaker protein-ligand interactions. The findings of thi …
The decrease in binding affinity (-3.74 kcal/mol) was consistent with RMSD, RMSF, SASA, PCA, and hydrogen bonding profiles, confirmin …
134 results